TNDM · Tandem Diabetes Care, Inc.

Tandem Diabetes Care delivered a materially improved first quarter 2026, marked by strong top-line growth, significant gross margin expansion, and a dramatic reduction in operating and net losses. Sales grew 5% year-over-year to $247.2 million, with U.S. sales rising 7% to $160.8 million and international sales up 3% to $86.4 million — though international growth was offset by foreign currency headwinds, resulting in a 5% decline in constant currency. Gross margin increased 480 basis points to 55%, reflecting favorable product mix, scale benefits, and supply chain improvements. The most notable improvement was in profitability: GAAP operating loss narrowed to $17.4 million (−7% of sales) from $120.9 million (−52% of sales) in Q1 2025, and GAAP net loss fell to $20.4 million from $130.6 million, largely due to the absence of a $75.2 million acquired IPR&D charge that distorted prior-year comparability. Adjusted EBITDA turned positive at $2.7 million (1% of sales), the first time in company history, underscoring progress toward sustainable profitability. Management attributed the performance to execution against its financial plan and strategic initiatives, including the U.S. launch of a pay-as-you-go reimbursement model in pharmacies and Android compatibility expansion for the Tandem Mobi ecosystem. The reaffirmation of full-year 2026 guidance — particularly the $1.065–$1.085 billion sales range and 56–57% gross margin target — signals confidence in continued momentum despite macro and reimbursement uncertainties. The balance sheet remains robust, with cash and equivalents rising to $570.3 million as of March 31, 2026, supported by the recent 0.00% convertible debt offering, which added long-term capital without near-term interest burden.